Bayer on Friday announced plans to invest $2.2 billion in a pharmaceutical manufacturing campus in the New Albany International Business Park, a project expected to create about 600 jobs and roughly 1,500 construction positions.
The planned campus will combine drug-substance and drug-product manufacturing in a flexible, modular operation that uses advanced digital and automation technologies. Bayer said the facility will support its portfolio in oncology, cardiovascular care and renal care.
The announcement represents one of Ohio’s largest biomanufacturing investments to date and adds Bayer to a growing life-sciences manufacturing cluster in New Albany.
By the numbers
- $2.2 billion: Bayer’s planned investment in the New Albany campus.
- About 600: Expected permanent jobs.
- About 1,500: Construction jobs expected during development.
- 2031: Target date for the first drug-substance manufacturing module to begin operating.
- 2034: Target date for the second, drug-product manufacturing module to follow.
“Bayer has long seen the United States as a key manufacturing base and innovation hub,” Bayer CEO Bill Anderson said of the announcement. “This landmark investment underscores our commitment.”
Why Ohio’s workforce mattered
Ohio officials said workforce readiness was a central part of the state’s case for the project…